.jpg "Editas Medicine Inc (NASDAQ: EDIT)")
Chardan Capital analyst Gbola Amusa maintained a Buy rating on Editas Medicine Inc (NASDAQ: EDIT) today. The company’s shares opened today at $38.59.
According to TipRanks.com, Amusa is a top 100 analyst with an average return of 30.0% and a 55.8% success rate. Amusa covers the Healthcare sector, focusing on stocks such as Spring Bank Pharmaceuticals Inc, Nightstar Therapeutics Limited, and Applied Genetic Technologies.
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Editas Medicine Inc with a $39 average price target.
See today’s analyst top recommended stocks >>
Based on Editas Medicine Inc’s latest earnings release for the quarter ending March 31, the company reported a quarterly GAAP net loss of $30.94 million. In comparison, last year the company had a GAAP net loss of $26.44 million.
Based on the recent corporate insider activity of 27 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of EDIT in relation to earlier this year.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Editas Medicine, Inc. engages in the development and commercialization of genome editing technology. Its technology includes clustered, regularly interspaced short palindromic repeats (CRISPR); and CRISPR associated protein 9 (Cas9).
